Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Part of paid clinical trials in Irvine, California.
- Sponsor
- Reprieve Cardiovascular, Inc
- Study ID
- NCT06898515
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Acute Decompensated Heart Failure
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Reprieve System — DEVICEThe Reprieve System is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
- furosemide infusion — DRUGParticipants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy
Study Details
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.
Key Dates
- Start date
- Jul 14, 2025
- Status verified
- Nov 2025
- Primary completion
- Aug 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 400 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Reprieve SystemParticipants randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
- Active Comparator: Optimal Diuretic Therapy (ODT)Participants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy
- No Intervention: RegistryParticipants will be treated per local site usual care.
Primary Outcome Measure
Hierarchical composite/win-ratio [ Time Frame: 1. up to 30 days from randomization, 2. up to 30 days from discharge, 3. up to 72 hours after randomization ]
Central Contacts
- Annemarie Forrest617-848-0400
Locations (37)
Find similar trials in Irvine, CA
Related Studies
- Low Level Tragus Stimulation in Acute Decompensated Heart FailureRecruiting · University of Oklahoma · Oklahoma City, Oklahoma
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart FailurePHASE3 · Not Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- A Study Of Acute Decompensated Heart FailureNot Yet Recruiting · Mayo Clinic · Rochester, Minnesota
- Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart FailureRecruiting · UConn Health · Farmington, Connecticut